Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21518489 | 0.83 | ALDH1A1 (0.49) | NPSR1KEAP1KMT2ALMNANPC1 | |
| SCHEMBL20323095 | 0.83 | GABRP (0.47) | NPSR1KMT2ALMNANPC1RAB9A | |
| SCHEMBL30227938 | 0.76 | IGLV6-57 (0.51) | NPSR1KMT2ALMNASMN1; SMN2CYP2C19 | |
| SCHEMBL23108697 | 0.76 | AHR (0.53) | NPSR1KMT2ALMNANPC1RAB9A | |
| SCHEMBL27110768 | 0.76 | AHR (0.53) | KMT2ALMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21518484 | 0.76 | SMN1; SMN2 (0.43) | NPSR1KMT2ALMNATTRNPC1 | |
| SCHEMBL14342106 | 0.75 | AHR (0.49) | NPSR1KMT2ALMNATTRNPC1 | |
| SCHEMBL30227948 | 0.74 | IGLV6-57 (0.51) | NPSR1KMT2ALMNASMN1; SMN2CYP2C19 | |
| SCHEMBL22857673 | 0.73 | AHR (0.50) | KMT2ALMNATTRNPC1RAB9A | |
| SCHEMBL6373552 | 0.72 | AHR (0.57) | NPSR1KMT2ALMNATTRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560928-B1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| EP-3560928-B1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2020-03-31 | — | — | US | disclosed |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2020-03-31 | — | — | US | disclosed |
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3560928-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2019-10-30 | — | — | EP | disclosed |
| EP-3560928-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018113624-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | 深圳微芯生物科技有限责任公司 | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | IDO1, IDO2, INMT | NPSR1 2518/4885KEAP1 306/4885KMT2A 209/4885 |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | IDO1, IDO2, INMT | NPSR1 1734/4885KEAP1 480/4885KMT2A 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.